NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $1.06 -0.04 (-3.64%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akebia Therapeutics Stock (NASDAQ:AKBA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$1.05▼$1.1350-Day Range$0.87▼$1.5652-Week Range$0.82▼$4.08Volume3.98 million shsAverage Volume5.45 million shsMarket Capitalization$284.36 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingHold Company Overview Akebia Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders. Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners. In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.AI Generated. May Contain Errors. Read More Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 718th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAkebia Therapeutics has a consensus price target of $4.67, representing about 340.3% upside from its current price of $1.06.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.10) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 8.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Akebia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.68% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 3.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 7 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKBA Stock News HeadlinesAkebia Therapeutics, Inc.: Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent PortfolioJune 10, 2026 | finanznachrichten.deAkebia Therapeutics Strengthens Vafseo® (vadadustat) Patent PortfolioJune 10, 2026 | globenewswire.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 24 at 1:00 AM | Behind the Markets (Ad)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comAkebia Therapeutics (AKBA) Receives a Buy from H.C. WainwrightMay 18, 2026 | theglobeandmail.comAnalysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.61 at the beginning of the year. Since then, AKBA stock has decreased by 34.2% and is now trading at $1.06. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.02. The biopharmaceutical company earned $53.54 million during the quarter, compared to analyst estimates of $51.67 million. Akebia Therapeutics had a negative net margin of 8.83% and a negative trailing twelve-month return on equity of 62.72%. Read the conference call transcript. When did Akebia Therapeutics IPO? Akebia Therapeutics (AKBA) raised $91 million in an initial public offering on Thursday, March 20th 2014. The company issued 5,882,353 shares at a price of $14.00-$17.00 per share. Who are Akebia Therapeutics' major shareholders? Top institutional investors of Akebia Therapeutics include Bank of America Corp DE (1.03%), Renaissance Technologies LLC (0.68%), Dimensional Fund Advisors LP (0.34%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, Erik Ostrowski, Nicholas Grund and Richard C Malabre. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and ExxonMobil (XOM). Company Calendar Last Earnings5/07/2026Today6/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 AKBA's financial health is in the Red zone, according to TradeSmith. AKBA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year Founded2007Price Target and Rating Average Price Target for Akebia Therapeutics$4.67 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+340.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net Margins-8.83% Pretax Margin-8.07% Return on Equity-62.72% Return on Assets-5.66% Debt Debt-to-Equity Ratio1.33 Current Ratio1.40 Quick Ratio1.33 Sales & Book Value Annual Sales$236.20 million Price / Sales1.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book8.83Miscellaneous Outstanding Shares268,260,000Free Float256,723,000Market Cap$284.36 million OptionableOptionable Beta0.26 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AKBA) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredWhy Miners Just Became the World's New AI LandlordsThe most valuable commodity in the AI revolution is power - and Google, Microsoft, and Amazon are in a global ...The Tomorrow Investor | SponsoredMan who predicted COVID 19 Crash warns of new crisisA former CIA and Pentagon economic advisor predicted the 2008 financial crisis two years early - a warning so ...Paradigm Press | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
